A recent in vitro study analyzed the efficacy of a combined therapy based on the use of vitD3-TolDC together with IFN-β in PBMCs from MS individuals whose results showed enhanced suppressive ability of vitD3-TolDC, representing a promising strategy for MS patients [87]. The gene discussed is IFNB1; the disease is myeloid sarcoma.